Sinsin Pharmaceutical Statistics

Total Valuation

Sinsin Pharmaceutical has a market cap or net worth of KRW 81.47 billion. The enterprise value is 121.45 billion.

Market Cap	81.47B
Enterprise Value	121.45B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Sinsin Pharmaceutical has 15.17 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	15.17M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	51.50%
Owned by Institutions (%)	n/a
Float	7.26M

Valuation Ratios

The trailing PE ratio is 20.46.

PE Ratio	20.46
Forward PE	n/a
PS Ratio	0.77
PB Ratio	1.24
P/TBV Ratio	1.25
P/FCF Ratio	23.70
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.62, with an EV/FCF ratio of 35.33.

EV / Earnings	30.48
EV / Sales	1.15
EV / EBITDA	11.62
EV / EBIT	19.47
EV / FCF	35.33

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.66.

Current Ratio	0.94
Quick Ratio	0.65
Debt / Equity	0.66
Debt / EBITDA	4.15
Debt / FCF	12.61
Interest Coverage	3.08

Financial Efficiency

Return on equity (ROE) is 6.04% and return on invested capital (ROIC) is 3.64%.

Return on Equity (ROE)	6.04%
Return on Assets (ROA)	3.05%
Return on Capital (ROIC)	3.64%
Revenue Per Employee	309.15M
Profits Per Employee	11.65M
Employee Count	342
Asset Turnover	0.83
Inventory Turnover	4.75

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.49% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.49%
50-Day Moving Average	5,547.80
200-Day Moving Average	5,928.25
Relative Strength Index (RSI)	48.56
Average Volume (20 Days)	79,752

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sinsin Pharmaceutical had revenue of KRW 105.73 billion and earned 3.98 billion in profits. Earnings per share was 262.49.

Revenue	105.73B
Gross Profit	35.27B
Operating Income	6.24B
Pretax Income	4.11B
Net Income	3.98B
EBITDA	10.45B
EBIT	6.24B
Earnings Per Share (EPS)	262.49

Full Income Statement

Balance Sheet

The company has 3.07 billion in cash and 43.34 billion in debt, giving a net cash position of -40.27 billion or -2,654.64 per share.

Cash & Cash Equivalents	3.07B
Total Debt	43.34B
Net Cash	-40.27B
Net Cash Per Share	-2,654.64
Equity (Book Value)	65.22B
Book Value Per Share	4,317.80
Working Capital	-3.75B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.89 billion and capital expenditures -3.46 billion, giving a free cash flow of 3.44 billion.

Operating Cash Flow	6.89B
Capital Expenditures	-3.46B
Free Cash Flow	3.44B
FCF Per Share	226.61

Full Cash Flow Statement

Margins

Gross margin is 33.36%, with operating and profit margins of 5.90% and 3.77%.

Gross Margin	33.36%
Operating Margin	5.90%
Pretax Margin	3.88%
Profit Margin	3.77%
EBITDA Margin	9.88%
EBIT Margin	5.90%
FCF Margin	3.25%

Dividends & Yields

This stock pays an annual dividend of 60.00, which amounts to a dividend yield of 1.12%.

Dividend Per Share	60.00
Dividend Yield	1.12%
Dividend Growth (YoY)	20.00%
Years of Dividend Growth	2
Payout Ratio	22.85%
Buyback Yield	n/a
Shareholder Yield	1.12%
Earnings Yield	4.89%
FCF Yield	4.22%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sinsin Pharmaceutical has an Altman Z-Score of 2.3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.3
Piotroski F-Score	n/a